Bacil Pharma Limited reported earnings results for the third quarter and nine months ended December 31, 2022. For the third quarter, the company reported revenue was INR 0.02 million compared to INR 0.157 million a year ago. Net loss was INR 0.445 million compared to INR 0.22 million a year ago. Basic loss per share from continuing operations was INR 0.08 compared to INR 0.04 a year ago. Diluted loss per share from continuing operations was INR 0.08 compared to INR 0.04 a year ago.
For the nine months, revenue was INR 1.06 million compared to INR 0.492 million a year ago. Net loss was INR 0.258 million compared to INR 1.23 million a year ago. Basic loss per share from continuing operations was INR 0.04 compared to INR 0.21 a year ago. Diluted loss per share from continuing operations was INR 0.04 compared to INR 0.21 a year ago.